Andere talen Lixte Biotechnology Holdings, Inc.

Aandelen

LIXT

US5393193017

Geschatte realtime Cboe BZX Andere beurzen 21:04:41 06-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,98 ^USD	+3,11%		-6,05%	+25,53%

23/04	Lixte Biotechnology dient tot $50 miljoen gemengde Shelf in	MT
27/03	Sectorupdate: Gezondheidszorgaandelen stijgen laat in de middag	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Lixte Biotechnology : Investor Presentation - April 2024	30/04
Lixte Biotechnology Files Up to $50 Million Mixed Shelf	23/04
Sector Update: Health Care Stocks Advance Late Afternoon	27/03
Top Midday Gainers	27/03
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	27/03
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES	27/03
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal	27/03
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	21/03
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	21/03
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research	27/02
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	26/02
LIXTE Biotechnology Holdings, Inc. Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	26/02
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial	29/01
Lixte Biotechnology Holdings, Inc. Announces Dosing of the First Patient in A Phase 1B/2 Clinical Trial to Assess Whether Adding Lixte?S Lb-100 to Gsk?S Programmed Death Receptor-1 (Pd-1)-Blocking Monoclonal Antibody, Dostarlimab-Gxly, May Enhance the Effectiveness of Immunotherapy in the Treatment of Ovarian Clear Cell Carcinoma	29/01
Top Premarket Decliners	28/11
Lixte Biotechnology : Investor Presentation - November 2023	20/11
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations	13/11
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Certain Common Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lixte Biotechnology Holdings, Inc.

Aandelen

LIXT

US5393193017

Andere talen

Filters